UDG Healthcare Public Limited Co. Board Appointment and Directorate Changes (3454T)
July 03 2018 - 2:00AM
UK Regulatory
TIDMUDG
RNS Number : 3454T
UDG Healthcare Public Limited Co.
03 July 2018
UDG Healthcare plc
Board Appointment & Directorate Changes
3 July 2018: UDG Healthcare plc (the "Company"), a leading
international healthcare services provider, is pleased to announce
the appointment of Mr Erik Van Snippenberg as a Non-Executive
Director of the Company with effect from 2 July 2018.
Erik spent almost thirty years at GlaxoSmithKline ("GSK") where
he held a number of senior executive roles in GSK's global
pharmaceutical business. Most recently, Erik held the position of
SVP & Area Head for Europe and Canada and was a member of GSK's
Global Pharmaceutical Management Team, Prior to this, Erik held a
number of Director and General Manager roles in Europe, including
SVP & Director of UK & Ireland and SVP & Director of
North and West Europe.
In addition to his deep industry experience, Erik has extensive
experience in product launches, product lifecycle management,
business development and strategy. Erik will also join the Audit
Committee with effect from 2 July 2018.
Separately, the Company also announces that Chris Corbin has
decided to bring forward his retirement date as Executive Chairman
of Ashfield to 30 June 2018.
As announced in September 2016, Mr Corbin was due to retire as
Executive Chairman of Ashfield and from the Board of the Company in
April 2019. However, at the request of the Company, Mr Corbin has
agreed to extend his term on the Board in a Non-Executive Director
capacity, subject to re-election at the Company's Annual General
Meeting.
Commenting on the announcements, Peter Gray, Chairman of UDG
Healthcare plc, said: "We are delighted that Erik has agreed to
join the Board. His strong European industry and management
experience will be a great asset as we continue to develop the UDG
Healthcare business internationally.
We are also delighted to retain Chris Corbin as a Non-Executive
director of UDG Healthcare. His deep experience and entrepreneurial
spirit continues to be hugely valued by the Board."
This announcement is made in accordance with Listing Rule 9.6.11
and there is no further information to be disclosed pursuant to
Listing Rule 9.6.13.
For further information, please contact:
Damien Moynagh Keith Byrne
General Counsel & Company Secretary Head of Investor Relations,
Strategy & Corporate Communications
UDG Healthcare plc UDG Healthcare plc
Tel: +353-1-468-9000 Tel: +353-1-468-9000
Lisa Kavanagh / Jack Hickey
Powerscourt
Tel: +44-207-250-1446
Email: udghealthcare@powerscourt-group.com
About UDG Healthcare plc
UDG Healthcare plc (LON: UDG) is a leading international partner
of choice delivering advisory, communication, commercial, clinical
and packaging services to the healthcare industry, employing 9,000
people with operations in 24 countries and delivering services in
over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield,
Sharp and Aquilant.
Ashfield - Ashfield is a global leader in commercialisation
services for the pharmaceutical and healthcare industry, operating
across three broad areas of activity: advisory, communications and
commercial & clinical services. It focuses on supporting
healthcare professionals and patients at all stages of the product
life cycle. The division provides field and contact centre sales
teams, healthcare communications, patient support, audit, advisory,
medical information and event management services to over 300
healthcare companies.
Sharp - Sharp is a global leader in contract commercial
packaging and clinical trial packaging services for the
pharmaceutical and biotechnology industries, operating from
state-of-the-art facilities in the US and Europe.
Aquilant - Aquilant is a leading distributor of specialist
medical and scientific products, providing outsourced sales,
marketing, distribution and engineering services to the medical and
scientific sectors in the UK and Ireland.
The company is listed on the London Stock Exchange and is a
constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAEAFXAEAPPEAF
(END) Dow Jones Newswires
July 03, 2018 02:00 ET (06:00 GMT)
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Apr 2023 to Apr 2024